Zoekstrategie versie 2.2 (2017) Her2neu

  
  Her2Neu > Bijlage    Sluit venster
 

Laatst gewijzigd : 2017-03-01 Verantwoording: Landelijke werkgroep Gastro-intestinale Tumoren Versie: 2.2 Type: Landelijke richtlijn

RL Maag – PICO Her2Neu

 

Methodology report

 

1   KEY QUESTION

 

  1. Bij patiënten met maagkanker op welk weefsel, primaire tumor of metastase, dient de HER2Neu test (welke precies? ) bij voorkeur uitgevoerd te worden met betrekking tot een betere sensitiviteit, specificiteit?

 

P patiënten met maagkanker (en metastasen?)

I biopt van primaire tumor

C biopt van metastase

O sensitiviteit specificiteit

 

  1. Bij patiënten met maagkanker die in aanmerking komen voor een Her2Neu test hoe betrouwbaar is de uitkomst indien de test op een biopt wordt verricht t.o.v. een resectie?
  2.  

P Patiënten met maagkanker

I biopt

C resectie

O percentage fout negatieven, percentage fout positieven, sensitiviteit, specificiteit.

 

2   GOLDEN HITS

 

  1. Abrahao-Machado 2013 World J gastroenterology
  2. Fassan 2012 Hum Pathol
  3. Kim 2011 Histopathol
  4. Mrklic 2012, Hepatogastroenterology
  5. Okines 2013, Ann Oncol
  6. Pirelli 2013 Dig Dis Sci
  7. Tsapralis, 2012 World J Gastroenterology
  8. Wang 2014 Hum Pathol
  9. Warneke 2013, Ann Oncol
  10. Yoshida 2014 Virchows Arch

3   SEARCH STRATEGY

The searches were run on 7 October 2015. Pubmed Medline, Embase, Cochrane CDSR, were searched. Detailed search strings are given below. The searches were limited to 2010-2015, English and Dutch. Study types: systematic reviews and meta-analysis, RCT and observational studies.

4   SEARCH RESULTS

4.1   Table of excluded references

#

Referentie

Inclusie/exclusie

Comments

1

Abrahão-Machado LF, Jácome AAA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JHTG, et al. HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World Journal of Gastroenterology. 2013; 19: 6438-46.

Included

Included for the biopsy versus resection PICO

2

Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Advances in anatomic pathology. 2011; 18: 53-9. 10.1097/PAP.0b013e3182026d72.

Excluded

Narrative review

3

Arez M, Butt MA, Gandy M, Sehgal V, Puccio I, Hamoudi R, et al. Expression patterns of human epidermal growth factor receptor proteins in early gastric cancer. Gut. 2015; 64: A484.

Excluded

Abstract

4

Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, et al. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2015; 19: 1565-71. 10.1007/s11605-015-2888-y.

Excluded

No Diagnostic Test Accuracy (DTA)  study

5

Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. British journal of cancer. 2011; 104: 1372-76.

Excluded

No DTA study

6

Emre H, Tekin SB, Dogan H, Cayir K, Bilici M, Sipal S, et al. Investigation of ErbB-2 overexpression on patients with gastric cancer in Eastern Anatolia of Turkey. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2013; 24: 211-7.

Excluded

No DTA study

7

Fassan M, Ludwig K, Pizzi M, Castoro C, Guzzardo V, Balistreri M, et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol. 2012; 43: 1206-12. 10.1016/j.humpath.2011.09.004.

Excluded

No DTA study

8

Gasljevic G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gasparov S. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. Pathology oncology research : POR. 2013; 19: 855-65. 10.1007/s12253-013-9654-9.

Excluded

No outcomes of interest reported

9

Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012; 25: 1566-73. 10.1038/modpathol.2012.125.

Excluded

No DTA study

10

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World journal of gastroenterology : WJG. 2013; 19: 2171-8. PMC3627881.

Excluded

No DTA study

11

Hedner C, Tran L, Borg D, Nodin B, Jirstrom K, Eberhard J. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology. 2015, 10.1111/his.12744.

Excluded

No DTA study

12

Ieni A, Barresi V, Caltabiano R, Caleo A, Bonetti LR, Lanzafame S, et al. Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis. International journal of molecular sciences. 2014; 15: 22331-41. PMC4284711.

Excluded

No DTA study

13

Jeung JA, Patel R, Vila L, Wakefield D, Liu C. Characterization of HER2 expression in primary gastroesophageal adenocarcinomas. Laboratory Investigation. 2011; 91: 153A-54A.

Excluded

Abstract

14

Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Annals of surgical oncology. 2011; 18: 2833-40. 10.1245/s10434-011-1695-2.

Excluded

No DTA study

15

Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011; 59: 822-31. PMC3267049.

Excluded

No DTA study

16

Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015; 18: 691-7. 10.1007/s10120-014-0430-7.

Excluded

No DTA study

17

Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: Results of the feasibility part of the SHIVA trial. British journal of cancer. 2014; 111: 17-24.

Excluded

No DTA study

18

Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011; 59: 832-40. 10.1111/j.1365-2559.2011.04017.x.

Excluded

No DTA study

19

Lee WS, Park YH, Lee JN, Baek JH, Lee TH, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer medicine. 2014; 3: 674-80. PMC4101759.

Excluded

No DTA study

20

Liang JW, Zhang JJ, Zhang T, Zheng ZC. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35: 4849-58. 10.1007/s13277-014-1636-3.

Excluded

No DTA study

21

Lorenzen S, Lordick F. Management of advanced gastric cancer: Current status and future therapeutic strategies. Onkologe. 2013; 19: 389-94.

Excluded

German

22

Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Critical reviews in oncology/hematology. 2012; 82: 310-22. 10.1016/j.critrevonc.2011.06.003.

Excluded

Narrative review

23

Marx AH, Simon R, Sauter G. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis - Reply. Human Pathology. 2011; 42: 910-11.

Excluded

Abstract

24

Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cellular oncology (Dordrecht). 2011; 34: 89-95. PMC3063579.

Excluded

No DTA study

25

Mrklic I, Bendic A, Kunac N, Bezic J, Forempoher G, Durdov MG, et al. Her-2/neu assessment for gastric carcinoma: validation of scoring system. Hepato-gastroenterology. 2012; 59: 300-3. 10.5754/hge10776.

Excluded

No DTA study

26

Negri FV, Bozzetti C, Ardizzoni A, Lagrasta C, Crafa P, Silini EM. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis. Hum Pathol. 2011; 42: 909-10; author reply 10-1. 10.1016/j.humpath.2011.01.016.

Excluded

Abstract

27

Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. HER2 status in primary and corresponding metastatic sites of gastric cancer. Annals of Oncology. 2011; 22: v19.

Excluded

Abstract

28

Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013:1253-61.10.1093/annonc/mds622.

Excluded

No DTA study

29

Okines AFC, Thompson LC, Cunningham D, Wotherspoon A, Reis-filho JS, Langley RE, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of Oncology. 2013; 24: 1253-61.

Excluded

Duplicate

30

Pazocid RA, Álvarez Alejandro M, Yus C, Remón L, Gil I, Madani J, et al. Clinical outcome of advanced gastric cancer (GC) patients (pts) by human epidermal growth factor receptor 2 (HER2) status when treated before the trastuzumab era. Annals of Oncology. 2010; 21: viii256.

Excluded

Abstract

31

Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Digestive diseases and sciences. 2013; 58: 397-404. 10.1007/s10620-012-2357-3.

Excluded

No DTA study

32

Rajagopal I, Niveditha SR, Sahadev R, Preethan KN, Rajendra SG. HER 2 expression in gastric and gastro-esophageal junction (GEJ) adenocarcinomas. Journal of Clinical and Diagnostic Research. 2015; 9: EC06-EC10.

Excluded

No DTA study

33

Saito T, Kondo C, Shitara K, Ito Y, Saito N, Ikehara Y, et al. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. Pathology international. 2015; 65: 309-17.

Excluded

Case serie

34

Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Castro DG, et al. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology 2013:3123-28.10.1093/annonc/mdt408.

Excluded

No DTA study

35

Tsapralis D, Panayiotides I, Peros G, Liakakos T, Karamitopoulou E. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World journal of gastroenterology : WJG. 2012; 18: 150-5. PMC3257442.

Excluded

No DTA study

36

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015; 18: 476-84. PMC4511072.

Excluded

No DTA study

37

Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014; 45: 970-5. 10.1016/j.humpath.2013.12.010.

Excluded

No DTA study

38

Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013; 24: 725-33. PMC3574551.

Excluded

No DTA study

39

Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MPA, et al. Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors. Annals of Oncology. 2013; 24: 725-33.

Excluded

Duplicate

40

Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World journal of gastroenterology : WJG. 2011; 17: 1501-6. PMC3070026.

Excluded

No DTA study

41

Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Archiv : an international journal of pathology. 2014; 465: 145-54. 10.1007/s00428-014-1597-3.

Excluded

No DTA study

42

Zhang YL, Hua YW, Zhang ZD, Ma F, Xu JL. HER-2 amplification and over expression in primary tumors and paired lymph node metastases of gastric cancer. World Chinese Journal of Digestology. 2012; 20: 2485-90.

Excluded

Chinese

 

Appendix

 

Medline via Pubmed (07-10-2015)

 

  1. Stomach[tiab] AND neoplas*[tiab] 3671
  2. Stomach[tiab] AND cancer*[tiab] 19808
  3. Stomach[tiab] AND carcin*[tiab] 11480
  4. Stomach[tiab] AND tumor*[tiab] 11918
  5. Stomach[tiab] AND tumour*[tiab] 2376
  6. Stomach[tiab] AND metasta*[tiab] 5126
  7. Stomach[tiab] AND malig*[tiab] 6157
  8. gastric[tiab] AND neoplas*[tiab] 6192
  9. gastric[tiab] AND cancer*[tiab] 52393
  10. gastric[tiab] AND carcin*[tiab] 26245
  11. gastric[tiab] AND tumor*[tiab] 27963
  12. gastric[tiab] AND tumour*[tiab] 4616
  13. gastric[tiab] AND metasta*[tiab] 15574
  14. gastric[tiab] AND malig*[tiab] 11331
  15. "Stomach Neoplasms"[Mesh] 77135
  16. 1-14/OR (((((((((((((((Stomach[tiab] AND neoplas*[tiab])) OR (Stomach[tiab] AND cancer*[tiab])) OR (Stomach[tiab] AND carcin*[tiab])) OR (Stomach[tiab] AND tumour*[tiab])) OR (Stomach[tiab] AND malig*[tiab])) OR (gastric[tiab] AND neoplas*[tiab])) OR (gastric[tiab] AND cancer*[tiab])) OR (gastric[tiab] AND carcin*[tiab])) OR (gastric[tiab] AND tumor*[tiab])) OR (gastric[tiab] AND tumour*[tiab])) OR (gastric[tiab] AND metasta*[tiab])) OR (gastric[tiab] AND malig*[tiab])) OR (Stomach[tiab] AND tumor*[tiab])) OR (Stomach[tiab] AND metasta*[tiab])) OR "Stomach Neoplasms"[Mesh] 113689Her2Neu[tiab] 79
  17.  
  18.  
  1. HER-2/neu[tiab] 2797
  2. "Receptor, ErbB-2"[Majr] 9142
  3. ErbB-2[tiab] 3730
  4. ERBB2[tiab] 4893
  5. Human Epidermal growth factor Receptor*[tiab] 4452
  6. 25 17-22/OR 19214

 

 

((((((her2neu[tiab]) OR HER-2/neu[tiab]) OR "Receptor, ErbB-2"[Majr]) OR ErbB-2[tiab]) OR ErBB2[tiab]) OR Human Epidermal growth factor Receptor*[tiab])

16 AND 25 993

Limit eng Dutch 2010-2015 539

Overall Pubmed search:

(((((((((((((((((Stomach[tiab] AND neoplas*[tiab])) OR (Stomach[tiab] AND cancer*[tiab])) OR (Stomach[tiab] AND carcin*[tiab])) OR (Stomach[tiab] AND tumour*[tiab])) OR (Stomach[tiab] AND malig*[tiab])) OR (gastric[tiab] AND neoplas*[tiab])) OR (gastric[tiab] AND cancer*[tiab])) OR (gastric[tiab] AND carcin*[tiab])) OR (gastric[tiab] AND tumor*[tiab])) OR (gastric[tiab] AND tumour*[tiab])) OR (gastric[tiab] AND metasta*[tiab])) OR (gastric[tiab] AND malig*[tiab])) OR (Stomach[tiab] AND tumor*[tiab])) OR (Stomach[tiab] AND metasta*[tiab])) OR "Stomach Neoplasms"[Mesh])) AND (((((((her2neu[tiab]) OR HER-2/neu[tiab]) OR "Receptor, ErbB-2"[Majr]) OR ErbB-2[tiab] ]) OR ErBB2[tiab]) OR Human Epidermal growth factor Receptor*[tiab]))

 

EMBASE (07-10-2015)

  1. 'stomach cancer'/exp OR (stomach NEAR/5 neoplas*):ab,ti OR (gastric NEAR/5 neoplas*):ab,ti OR (stomach NEAR/5 cancer*):ab,ti OR (gastric NEAR/5 cancer*):ab,ti OR (stomach NEAR/5 carcin*):ab,ti OR (gastric NEAR/5 carcin*):ab,ti OR (stomach NEAR/5 tumo*):ab,ti OR (gastric NEAR/5 tumo*):ab,ti OR (stomach NEAR/5 metasta*):ab,ti OR (gastric NEAR/5 metasta*):ab,ti OR (stomach NEAR/5 malig*):ab,ti OR (gastric NEAR/5 malig*):ab,ti
  2. her2:ab,ti AND neu:ab,ti 4448
  3. 'erbb2 protein'/exp OR 'erbb2 protein' 27895
  4. 'erbb 2 receptor'/exp OR 'erbb 2 receptor' 27901
  5. 'human epidermal growth factor receptor 2' 4343
  6. (h

    RL Maag – PICO Her2Neu

     

    Methodology report

     

    1   KEY QUESTION

     

    1. Bij patiënten met maagkanker op welk weefsel, primaire tumor of metastase, dient de HER2Neu test (welke precies? ) bij voorkeur uitgevoerd te worden met betrekking tot een betere sensitiviteit, specificiteit?

     

    P patiënten met maagkanker (en metastasen?)

    I biopt van primaire tumor

    C biopt van metastase

    O sensitiviteit specificiteit

     

    1. Bij patiënten met maagkanker die in aanmerking komen voor een Her2Neu test hoe betrouwbaar is de uitkomst indien de test op een biopt wordt verricht t.o.v. een resectie?
    2.  

    P Patiënten met maagkanker

    I biopt

    C resectie

    O percentage fout negatieven, percentage fout positieven, sensitiviteit, specificiteit.

     

    2   GOLDEN HITS

     

    1. Abrahao-Machado 2013 World J gastroenterology
    2. Fassan 2012 Hum Pathol
    3. Kim 2011 Histopathol
    4. Mrklic 2012, Hepatogastroenterology
    5. Okines 2013, Ann Oncol
    6. Pirelli 2013 Dig Dis Sci
    7. Tsapralis, 2012 World J Gastroenterology
    8. Wang 2014 Hum Pathol
    9. Warneke 2013, Ann Oncol
    10. Yoshida 2014 Virchows Arch

    3   SEARCH STRATEGY

    The searches were run on 7 October 2015. Pubmed Medline, Embase, Cochrane CDSR, were searched. Detailed search strings are given below. The searches were limited to 2010-2015, English and Dutch. Study types: systematic reviews and meta-analysis, RCT and observational studies.

    4   SEARCH RESULTS

    4.1   Table of excluded references

    #

    Referentie

    Inclusie/exclusie

    Comments

    1

    Abrahão-Machado LF, Jácome AAA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JHTG, et al. HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World Journal of Gastroenterology. 2013; 19: 6438-46.

    Included

    Included for the biopsy versus resection PICO

    2

    Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Advances in anatomic pathology. 2011; 18: 53-9. 10.1097/PAP.0b013e3182026d72.

    Excluded

    Narrative review

    3

    Arez M, Butt MA, Gandy M, Sehgal V, Puccio I, Hamoudi R, et al. Expression patterns of human epidermal growth factor receptor proteins in early gastric cancer. Gut. 2015; 64: A484.

    Excluded

    Abstract

    4

    Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, et al. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2015; 19: 1565-71. 10.1007/s11605-015-2888-y.

    Excluded

    No Diagnostic Test Accuracy (DTA)  study

    5

    Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. British journal of cancer. 2011; 104: 1372-76.

    Excluded

    No DTA study

    6

    Emre H, Tekin SB, Dogan H, Cayir K, Bilici M, Sipal S, et al. Investigation of ErbB-2 overexpression on patients with gastric cancer in Eastern Anatolia of Turkey. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2013; 24: 211-7.

    Excluded

    No DTA study

    7

    Fassan M, Ludwig K, Pizzi M, Castoro C, Guzzardo V, Balistreri M, et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol. 2012; 43: 1206-12. 10.1016/j.humpath.2011.09.004.

    Excluded

    No DTA study

    8

    Gasljevic G, Lamovec J, Contreras JA, Zadnik V, Blas M, Gasparov S. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. Pathology oncology research : POR. 2013; 19: 855-65. 10.1007/s12253-013-9654-9.

    Excluded

    No outcomes of interest reported

    9

    Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012; 25: 1566-73. 10.1038/modpathol.2012.125.

    Excluded

    No DTA study

    10

    He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World journal of gastroenterology : WJG. 2013; 19: 2171-8. PMC3627881.

    Excluded

    No DTA study

    11

    Hedner C, Tran L, Borg D, Nodin B, Jirstrom K, Eberhard J. Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology. 2015, 10.1111/his.12744.

    Excluded

    No DTA study

    12

    Ieni A, Barresi V, Caltabiano R, Caleo A, Bonetti LR, Lanzafame S, et al. Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis. International journal of molecular sciences. 2014; 15: 22331-41. PMC4284711.

    Excluded

    No DTA study

    13

    Jeung JA, Patel R, Vila L, Wakefield D, Liu C. Characterization of HER2 expression in primary gastroesophageal adenocarcinomas. Laboratory Investigation. 2011; 91: 153A-54A.

    Excluded

    Abstract

    14

    Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Annals of surgical oncology. 2011; 18: 2833-40. 10.1245/s10434-011-1695-2.

    Excluded

    No DTA study

    15

    Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011; 59: 822-31. PMC3267049.

    Excluded

    No DTA study

    16

    Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015; 18: 691-7. 10.1007/s10120-014-0430-7.

    Excluded

    No DTA study

    17

    Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: Results of the feasibility part of the SHIVA trial. British journal of cancer. 2014; 111: 17-24.

    Excluded

    No DTA study

    18

    Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011; 59: 832-40. 10.1111/j.1365-2559.2011.04017.x.

    Excluded

    No DTA study

    19

    Lee WS, Park YH, Lee JN, Baek JH, Lee TH, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer medicine. 2014; 3: 674-80. PMC4101759.

    Excluded

    No DTA study

    20

    Liang JW, Zhang JJ, Zhang T, Zheng ZC. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35: 4849-58. 10.1007/s13277-014-1636-3.

    Excluded

    No DTA study

    21

    Lorenzen S, Lordick F. Management of advanced gastric cancer: Current status and future therapeutic strategies. Onkologe. 2013; 19: 389-94.

    Excluded

    German

    22

    Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Critical reviews in oncology/hematology. 2012; 82: 310-22. 10.1016/j.critrevonc.2011.06.003.

    Excluded

    Narrative review

    23

    Marx AH, Simon R, Sauter G. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis - Reply. Human Pathology. 2011; 42: 910-11.

    Excluded

    Abstract

    24

    Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cellular oncology (Dordrecht). 2011; 34: 89-95. PMC3063579.

    Excluded

    No DTA study

    25

    Mrklic I, Bendic A, Kunac N, Bezic J, Forempoher G, Durdov MG, et al. Her-2/neu assessment for gastric carcinoma: validation of scoring system. Hepato-gastroenterology. 2012; 59: 300-3. 10.5754/hge10776.

    Excluded

    No DTA study

    26

    Negri FV, Bozzetti C, Ardizzoni A, Lagrasta C, Crafa P, Silini EM. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis. Hum Pathol. 2011; 42: 909-10; author reply 10-1. 10.1016/j.humpath.2011.01.016.

    Excluded

    Abstract

    27

    Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. HER2 status in primary and corresponding metastatic sites of gastric cancer. Annals of Oncology. 2011; 22: v19.

    Excluded

    Abstract

    28

    Okines AF, Thompson LC, Cunningham D, Wotherspoon A, Reis-Filho JS, Langley RE, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013:1253-61.10.1093/annonc/mds622.

    Excluded

    No DTA study

    29

    Okines AFC, Thompson LC, Cunningham D, Wotherspoon A, Reis-filho JS, Langley RE, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of Oncology. 2013; 24: 1253-61.

    Excluded

    Duplicate

    30

    Pazocid RA, Álvarez Alejandro M, Yus C, Remón L, Gil I, Madani J, et al. Clinical outcome of advanced gastric cancer (GC) patients (pts) by human epidermal growth factor receptor 2 (HER2) status when treated before the trastuzumab era. Annals of Oncology. 2010; 21: viii256.

    Excluded

    Abstract

    31

    Pirrelli M, Caruso ML, Di Maggio M, Armentano R, Valentini AM. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Digestive diseases and sciences. 2013; 58: 397-404. 10.1007/s10620-012-2357-3.

    Excluded

    No DTA study

    32

    Rajagopal I, Niveditha SR, Sahadev R, Preethan KN, Rajendra SG. HER 2 expression in gastric and gastro-esophageal junction (GEJ) adenocarcinomas. Journal of Clinical and Diagnostic Research. 2015; 9: EC06-EC10.

    Excluded

    No DTA study

    33

    Saito T, Kondo C, Shitara K, Ito Y, Saito N, Ikehara Y, et al. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. Pathology international. 2015; 65: 309-17.

    Excluded

    Case serie

    34

    Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Castro DG, et al. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology 2013:3123-28.10.1093/annonc/mdt408.

    Excluded

    No DTA study

    35

    Tsapralis D, Panayiotides I, Peros G, Liakakos T, Karamitopoulou E. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World journal of gastroenterology : WJG. 2012; 18: 150-5. PMC3257442.

    Excluded

    No DTA study

    36

    Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015; 18: 476-84. PMC4511072.

    Excluded

    No DTA study

    37

    Wang T, Hsieh ET, Henry P, Hanna W, Streutker CJ, Grin A. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014; 45: 970-5. 10.1016/j.humpath.2013.12.010.

    Excluded

    No DTA study

    38

    Warneke VS, Behrens HM, Boger C, Becker T, Lordick F, Ebert MP, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2013; 24: 725-33. PMC3574551.

    Excluded

    No DTA study

    39

    Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MPA, et al. Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors. Annals of Oncology. 2013; 24: 725-33.

    Excluded

    Duplicate

    40

    Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World journal of gastroenterology : WJG. 2011; 17: 1501-6. PMC3070026.

    Excluded

    No DTA study

    41

    Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Archiv : an international journal of pathology. 2014; 465: 145-54. 10.1007/s00428-014-1597-3.

    Excluded

    No DTA study

    42

    Zhang YL, Hua YW, Zhang ZD, Ma F, Xu JL. HER-2 amplification and over expression in primary tumors and paired lymph node metastases of gastric cancer. World Chinese Journal of Digestology. 2012; 20: 2485-90.

    Excluded

    Chinese

     

    Appendix

     

    Medline via Pubmed (07-10-2015)

     

    1. Stomach[tiab] AND neoplas*[tiab] 3671
    2. Stomach[tiab] AND cancer*[tiab] 19808
    3. Stomach[tiab] AND carcin*[tiab] 11480
    4. Stomach[tiab] AND tumor*[tiab] 11918
    5. Stomach[tiab] AND tumour*[tiab] 2376
    6. Stomach[tiab] AND metasta*[tiab] 5126
    7. Stomach[tiab] AND malig*[tiab] 6157
    8. gastric[tiab] AND neoplas*[tiab] 6192
    9. gastric[tiab] AND cancer*[tiab] 52393
    10. gastric[tiab] AND carcin*[tiab] 26245
    11. gastric[tiab] AND tumor*[tiab] 27963
    12. gastric[tiab] AND tumour*[tiab] 4616
    13. gastric[tiab] AND metasta*[tiab] 15574
    14. gastric[tiab] AND malig*[tiab] 11331
    15. "Stomach Neoplasms"[Mesh] 77135
    16. 1-14/OR (((((((((((((((Stomach[tiab] AND neoplas*[tiab])) OR (Stomach[tiab] AND cancer*[tiab])) OR (Stomach[tiab] AND carcin*[tiab])) OR (Stomach[tiab] AND tumour*[tiab])) OR (Stomach[tiab] AND malig*[tiab])) OR (gastric[tiab] AND neoplas*[tiab])) OR (gastric[tiab] AND cancer*[tiab])) OR (gastric[tiab] AND carcin*[tiab])) OR (gastric[tiab] AND tumor*[tiab])) OR (gastric[tiab] AND tumour*[tiab])) OR (gastric[tiab] AND metasta*[tiab])) OR (gastric[tiab] AND malig*[tiab])) OR (Stomach[tiab] AND tumor*[tiab])) OR (Stomach[tiab] AND metasta*[tiab])) OR "Stomach Neoplasms"[Mesh] 113689Her2Neu[tiab] 79
    17.  
    18.  
    1. HER-2/neu[tiab] 2797
    2. "Receptor, ErbB-2"[Majr] 9142
    3. ErbB-2[tiab] 3730
    4. ERBB2[tiab] 4893
    5. Human Epidermal growth factor Receptor*[tiab] 4452
    6. 25 17-22/OR 19214

     

     

    ((((((her2neu[tiab]) OR HER-2/neu[tiab]) OR "Receptor, ErbB-2"[Majr]) OR ErbB-2[tiab]) OR ErBB2[tiab]) OR Human Epidermal growth factor Receptor*[tiab])

    16 AND 25 993

    Limit eng Dutch 2010-2015 539

    Overall Pubmed search:

    (((((((((((((((((Stomach[tiab] AND neoplas*[tiab])) OR (Stomach[tiab] AND cancer*[tiab])) OR (Stomach[tiab] AND carcin*[tiab])) OR (Stomach[tiab] AND tumour*[tiab])) OR (Stomach[tiab] AND malig*[tiab])) OR (gastric[tiab] AND neoplas*[tiab])) OR (gastric[tiab] AND cancer*[tiab])) OR (gastric[tiab] AND carcin*[tiab])) OR (gastric[tiab] AND tumor*[tiab])) OR (gastric[tiab] AND tumour*[tiab])) OR (gastric[tiab] AND metasta*[tiab])) OR (gastric[tiab] AND malig*[tiab])) OR (Stomach[tiab] AND tumor*[tiab])) OR (Stomach[tiab] AND metasta*[tiab])) OR "Stomach Neoplasms"[Mesh])) AND (((((((her2neu[tiab]) OR HER-2/neu[tiab]) OR "Receptor, ErbB-2"[Majr]) OR ErbB-2[tiab] ]) OR ErBB2[tiab]) OR Human Epidermal growth factor Receptor*[tiab]))

     

    EMBASE (07-10-2015)

    1. 'stomach cancer'/exp OR (stomach NEAR/5 neoplas*):ab,ti OR (gastric NEAR/5 neoplas*):ab,ti OR (stomach NEAR/5 cancer*):ab,ti OR (gastric NEAR/5 cancer*):ab,ti OR (stomach NEAR/5 carcin*):ab,ti OR (gastric NEAR/5 carcin*):ab,ti OR (stomach NEAR/5 tumo*):ab,ti OR (gastric NEAR/5 tumo*):ab,ti OR (stomach NEAR/5 metasta*):ab,ti OR (gastric NEAR/5 metasta*):ab,ti OR (stomach NEAR/5 malig*):ab,ti OR (gastric NEAR/5 malig*):ab,ti
    2. her2:ab,ti AND neu:ab,ti 4448
    3. 'erbb2 protein'/exp OR 'erbb2 protein' 27895
    4. 'erbb 2 receptor'/exp OR 'erbb 2 receptor' 27901
    5. 'human epidermal growth factor receptor 2' 4343
    6. (her2:ab,ti AND neu:ab,ti) OR 'erbb2 protein'/exp OR 'erbb2 protein' OR 'erbb 2 receptor'/exp OR 'erbb 2 receptor'OR 'human epidermal growth factor receptor 2’
    7. 1 AND 6 1453
    8. Limit 2010-2015 Eng Ned Limit Eng Ned 1031

     

    Cochrane (07-10-2015)

     

    1. [Stomach Neoplasms]
    2. “Her2”
    3. 1 and 2 12
    er2:ab,ti AND neu:ab,ti) OR 'erbb2 protein'/exp OR 'erbb2 protein' OR 'erbb 2 receptor'/exp OR 'erbb 2 receptor'OR 'human epidermal growth factor receptor 2’
  7. 1 AND 6 1453
  8. Limit 2010-2015 Eng Ned Limit Eng Ned 1031

 

Cochrane (07-10-2015)

 

  1. [Stomach Neoplasms]
  2. “Her2”
  3. 1 and 2 12